Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17112338 | 0.91 | CYP2C19 (0.34) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL17111911 | 0.86 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL17234477 | 0.80 | ECE1 (0.42) | — | |
| SCHEMBL4047411 | 0.74 | CYP2D6 (0.45) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL21451502 | 0.73 | — | — | |
| SCHEMBL8244841 | 0.73 | — | — | |
| Iodide SCHEMBL28682486 | 0.73 | EGLN1 (0.40) | ALDH1A1 | |
| Iodide SCHEMBL11683597 | 0.71 | — | — | |
| SCHEMBL31613206 | 0.71 | CYP2D6 (0.43) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7440465 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511328-B1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-09-03 | — | — | US | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3511328-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| EP-3122745-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| WO-2015148379-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CYP2D6 84/4885CYP2C19 50/4885ALDH1A1 431/4885 |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CYP2D6 84/4885CYP2C19 50/4885ALDH1A1 431/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | CYP2D6 84/4885CYP2C19 50/4885ALDH1A1 431/4885 |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | CYP2D6 84/4885CYP2C19 50/4885ALDH1A1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.